Table 5. Number of expected drug-phenotype co-occurrences of highest priority according to CPIC guidelines (CPIC level A) or high clinical significance according to DPWG guidelines (DPWG clinical significance classes C–F) within the observed four-year time window.
PGx drugs included in all estimations: amitriptyline, azathioprine, clomipramine, clopidogrel, doxepin, glimepiride, haloperidol, imipramine, mercaptopurine, metoprolol, nortriptyline, paroxetine, propafenone, risperidone sertraline, tamoxifen, thioguanine, tramadol, venlafaxine. Estimations which additionally included codeine are shown for comparison. The rationale for including / excluding drug substances is described in the Methods section (‘Drug substances included in the estimation’).
| CCAE (age 0–13) | CCAE (age 14–39) | CCAE (age 40–64) | Medicaid (age 0–13) | Medicaid (age 14–39) | Medicaid (age 40–64) | Medicare (age > = 65) | |
|---|---|---|---|---|---|---|---|
| n | 9 893 962 | 22 824 848 | 26 561 525 | 4 151 506 | 3 032 191 | 1 130 797 | 5 429 266 |
| CPIC (excluding codeine) | |||||||
| CPIC level A | 3 317 (0.0%) | 53 341 (0.2%) | 223 915 (0.4%) | 1 919 (0.0%) | 12 149 (0.4%) | 11 252 (1.0%) | 111 095 (2.0%) |
| CPIC (including codeine) | |||||||
| CPIC level A | 31 189 (0.3%) | 137 906 (0.6%) | 445 607 (0.8%) | 15 370 (0.4%) | 23 866 (0.8%) | 14 183 (1.3%) | 128 905 (2.4%) |
| DPWG (excluding codeine) | |||||||
| DPWG class C | 10 324 (0.1%) | 155 461 (0.7%) | 285 894 (1.1%) | 9 225 (0.2%) | 39 739 (1.3%) | 27 680 (2.4%) | 82 003(1.5%) |
| DPWG class D | 2 840 (0.0%) | 19 141 (0.1%) | 84 057 (0.3%) | 2 167 (0.1%) | 4 728 (0.2%) | 6 739 (0.6%) | 41 927 (0.8%) |
| DPWG class E | 352 (0.0%) | 959 (0.0%) | 8 463 (0.0%) | 148 (0.0%) | 109 (0.0%) | 757 (0.1%) | 2 786 (0.1%) |
| DPWG class F | 265 (0.0%) | 5 921 (0.0%) | 120 556 (0.5%) | 157 (0.0%) | 1 361 (0.0%) | 13 745 (1.2%) | 91 346 (1.7%) |
| Sum of DPWG class C—F | 13 781 (0.1%) | 181 482 (0.8%) | 605 534 (1.9%) | 11 697 (0.3%) | 59 694 (1.5%) | 48 921 (4.3%) | 218 062 (4.1%) |
| DPWG (including codeine) a | |||||||
| Sum of DPWG class C—F | 41 653 (0.4%) | 266 047 (1.2%) | 598 302 (2.3%) | 25 147 (0.6%) | 57 654 (1.9%) | 51 852 (4.6%) | 235 871 (4.4%) |
a Detailed per-class estimates including codeine were omitted here; full data can be found in S7 Table. CPIC: Clinical Pharmacogenetics Implementation Consortium. DPWG: Dutch Pharmacogenetics Working Group. CCAE: Truven MarketScan® Commercial Claims and Encounters dataset.